- Relapsed chronic lymphocytic leukemia (CLL), in combination with rituximab, in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities
- Relapsed follicular B-cell non-Hodgkin lymphoma (FL) in patients who have received at least two prior systemic therapies
- Relapsed small lymphocytic lymphoma (SLL) in patients who have received at least two prior systemic therapies
- Limitation of Use: Zydelig is not indicated and is not recommended for first-line treatment of any patient.
Coverage of drugs is first determined by the member’s pharmacy or medical benefit. Please consult with or refer to the Evidence of Coverage document.